| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Natalia Mansur Haddad, Leonardo Peroni De Jesus, Mauricio Serpa, Martinus Van De Bilt, Leda Talib, Alana Costa, Wagner Gattaz, Alexandre Andrade Loc. Endocannabinoid system alterations in schizophrenia: association with cannabis use and antipsychotic medication. European archives of psychiatry and clinical neuroscience. 2024-03-19. PMID:38502208. |
a final sample of 93 individuals was divided into 3 groups: patients with schizophrenia using clozapine (treatment-resistant) (n = 29), patients with schizophrenia using another antipsychotic (n = 31), and controls (n = 33). |
2024-03-19 |
2024-03-23 |
Not clear |
| Natalia Mansur Haddad, Leonardo Peroni De Jesus, Mauricio Serpa, Martinus Van De Bilt, Leda Talib, Alana Costa, Wagner Gattaz, Alexandre Andrade Loc. Endocannabinoid system alterations in schizophrenia: association with cannabis use and antipsychotic medication. European archives of psychiatry and clinical neuroscience. 2024-03-19. PMID:38502208. |
regarding the cb2 receptor, the values of patients with schizophrenia and controls were similar, but those of patients using antipsychotics other than clozapine differed (p = 0.022). |
2024-03-19 |
2024-03-23 |
Not clear |
| Christoph U Correll, Celso Arango, Birgitte Fagerlund, Silvana Galderisi, Martien J Kas, Stefan Leuch. Identification and treatment of individuals with childhood-onset and early-onset schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 82. 2024-03-16. PMID:38492329. |
since early age of illness onset is a consistent risk factor for treatment-resistant schizophrenia (trs), clinicians need to be competent in diagnosing trs and using clozapine. |
2024-03-16 |
2024-03-19 |
Not clear |
| Massimo Berneri, Uma Jha, Seán O'Halloran, Sam Salman, Shanek Wickramasinghe, Kevin Kendrick, Jessica Nguyen, David A Joyc. Validation of Population Pharmacokinetic Models for Clozapine Dosage Prediction. Therapeutic drug monitoring. 2024-03-06. PMID:38446630. |
clozapine is unique in its capacity to ameliorate severe schizophrenia but at high risk of toxicity. |
2024-03-06 |
2024-03-09 |
Not clear |
| Mark Ainsley Colij. Clozapine Use in 22q11.2 Deletion Syndrome: A Systematic Review of the Literature. Journal of clinical psychopharmacology. 2024-02-26. PMID:38407281. |
while current recommendations regarding the management of psychotic symptoms in affected individuals are generally in keeping with treatment guidelines for general schizophrenia populations, evidence for the use of clozapine has come from case reports and retrospective observational data. |
2024-02-26 |
2024-02-28 |
Not clear |
| Yuki Kikuchi, Hiroshi Komatsu, Yuji Otsuka, Fumiaki Ito, Yuji Yada, Hiroaki Tanifuji, Hiroaki Tomit. Effect of concomitant use of valproic acid during clozapine initiation on clozapine-induced inflammation among Japanese patients with schizophrenia. Psychiatry research. vol 334. 2024-02-21. PMID:38382186. |
effect of concomitant use of valproic acid during clozapine initiation on clozapine-induced inflammation among japanese patients with schizophrenia. |
2024-02-21 |
2024-02-24 |
Not clear |
| Yumi Hirato, Kaoru Seiriki, Leo Kojima, Shohei Yamada, Hiroki Rokujo, Tomoya Takemoto, Takanobu Nakazawa, Atsushi Kasai, Hitoshi Hashimot. Clozapine Induces Neuronal Activation in the Medial Prefrontal Cortex in a Projection Target-Biased Manner. Biological & pharmaceutical bulletin. vol 47. issue 2. 2024-02-21. PMID:38382927. |
clozapine is an atypical antipsychotic drug used for treatment-resistant schizophrenia and is known to modulate neuronal activity in the mpfc. |
2024-02-21 |
2024-02-24 |
Not clear |
| Amit Jagtiani, Tarika Nagi, Raghu Gandhi, Abid Rizv. Clozapine Withdrawal Catatonia: A Case Report. Cureus. vol 16. issue 1. 2024-02-19. PMID:38370988. |
it has been reported to be a consequence of abrupt discontinuation of clozapine, an antipsychotic used for treatment-resistant schizophrenia. |
2024-02-19 |
2024-02-21 |
Not clear |
| Masaru Tsukahara, Ryuhei So, Yusaku Yoshimura, Shinichiro Nakajima, Hiroyoshi Takeuch. Response to the letter to the Editor from Araujo and colleagues on the research article entitled, "Effect of smoking habits and concomitant valproic acid use on relapse in patients with treatment-resistant schizophrenia receiving clozapine: A 1-year retrospective cohort study". Acta psychiatrica Scandinavica. 2024-02-15. PMID:38359861. |
response to the letter to the editor from araujo and colleagues on the research article entitled, "effect of smoking habits and concomitant valproic acid use on relapse in patients with treatment-resistant schizophrenia receiving clozapine: a 1-year retrospective cohort study". |
2024-02-15 |
2024-02-18 |
Not clear |
| C Casetta, P Santosh, R Bayley, J Bisson, S Byford, C Dixon, R J Drake, R Elvins, R Emsley, N Fung, D Hayes, O Howes, A James, K James, R Jones, H Killaspy, B Lennox, L Marchant, P McGuire, E Oloyede, M Rogdaki, R Upthegrove, J Walters, A Egerton, J H MacCab. CLEAR - clozapine in early psychosis: study protocol for a multi-centre, randomised controlled trial of clozapine vs other antipsychotics for young people with treatment resistant schizophrenia in real world settings. BMC psychiatry. vol 24. issue 1. 2024-02-14. PMID:38355533. |
clear - clozapine in early psychosis: study protocol for a multi-centre, randomised controlled trial of clozapine vs other antipsychotics for young people with treatment resistant schizophrenia in real world settings. |
2024-02-14 |
2024-02-17 |
Not clear |
| C Casetta, P Santosh, R Bayley, J Bisson, S Byford, C Dixon, R J Drake, R Elvins, R Emsley, N Fung, D Hayes, O Howes, A James, K James, R Jones, H Killaspy, B Lennox, L Marchant, P McGuire, E Oloyede, M Rogdaki, R Upthegrove, J Walters, A Egerton, J H MacCab. CLEAR - clozapine in early psychosis: study protocol for a multi-centre, randomised controlled trial of clozapine vs other antipsychotics for young people with treatment resistant schizophrenia in real world settings. BMC psychiatry. vol 24. issue 1. 2024-02-14. PMID:38355533. |
clozapine is an antipsychotic drug with unique efficacy, and it is the only recommended treatment for treatment-resistant schizophrenia (trs: failure to respond to at least two different antipsychotics). |
2024-02-14 |
2024-02-17 |
Not clear |
| Philippe D Vincent, Alain Lesage, Pierre Lalonde, Olivier Lipp, Vincent De Guire, Marie-Pierre Desbiens, Georgios Schoretsaniti. A Short Turnaround of Clozapine Blood Level Results Within 6 hours is Essential for Effective Management of Severely Ill Persons with Treatment-Resistant Schizophrenia. Therapeutic drug monitoring. 2024-02-13. PMID:38347672. |
a short turnaround of clozapine blood level results within 6 hours is essential for effective management of severely ill persons with treatment-resistant schizophrenia. |
2024-02-13 |
2024-02-15 |
Not clear |
| b' M Nov\\xc3\\xa1kov\\xc3\\xa1, T Hammer, E Nov\\xc3\\xa1kov\\xc3\\xa1, M Mayerov\\xc3\\xa1, L Ustohal, Hana Kotolov\\xc3\\xa. Potential impact on mental health in patients with treatment-resistant schizophrenia - clozapine augmentation with long-acting parenteral antipsychotics: a case series. Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti. vol 72. issue 6. 2024-02-12. PMID:38346905.' |
potential impact on mental health in patients with treatment-resistant schizophrenia - clozapine augmentation with long-acting parenteral antipsychotics: a case series. |
2024-02-12 |
2024-02-15 |
Not clear |
| Jae Hee Cho, Hindol Mukherjee, Vladimir Sazhi. Is antipsychotic augmentation associated with improved functioning in patients on clozapine? Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists. 2024-02-08. PMID:38330162. |
we aimed at exploring the relationship between functional outcomes in patients on clozapine augmented with antipsychotics in treatment-resistant schizophrenia using standard outcome measures health of nation outcome scales (honos) and life skills profile (lsp-16). |
2024-02-08 |
2024-02-11 |
Not clear |
| Aikaterini Dima, Ahmed Abdelsamie, Raquel Clark-Castillo, Henrietta Webb-Wilson, Sukhwinder S Shergill, Biba Stanton, Fiona Gaughran, Eromona Whiskey, Maria Antonietta Netti. Overcoming Obstacles to Clozapine Treatment: A Case of Clozapine Rechallenge in ECT-Resistant Schizophrenia With Catatonic Features. Journal of clinical psychopharmacology. 2024-02-05. PMID:38315142. |
overcoming obstacles to clozapine treatment: a case of clozapine rechallenge in ect-resistant schizophrenia with catatonic features. |
2024-02-05 |
2024-02-09 |
Not clear |
| Djenifer B Kappel, Elliott Rees, Eilidh Fenner, Adrian King, John Jansen, Marinka Helthuis, Michael J Owen, Michael C O'Donovan, James T R Walters, Antonio F Pardiña. Rare variants in pharmacogenes influence clozapine metabolism in individuals with schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 80. 2024-02-04. PMID:38310750. |
rare variants in pharmacogenes influence clozapine metabolism in individuals with schizophrenia. |
2024-02-04 |
2024-02-07 |
Not clear |
| Djenifer B Kappel, Elliott Rees, Eilidh Fenner, Adrian King, John Jansen, Marinka Helthuis, Michael J Owen, Michael C O'Donovan, James T R Walters, Antonio F Pardiña. Rare variants in pharmacogenes influence clozapine metabolism in individuals with schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 80. 2024-02-04. PMID:38310750. |
clozapine is the only licensed medication for treatment-resistant schizophrenia (trs). |
2024-02-04 |
2024-02-07 |
Not clear |
| Djenifer B Kappel, Elliott Rees, Eilidh Fenner, Adrian King, John Jansen, Marinka Helthuis, Michael J Owen, Michael C O'Donovan, James T R Walters, Antonio F Pardiña. Rare variants in pharmacogenes influence clozapine metabolism in individuals with schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 80. 2024-02-04. PMID:38310750. |
here, we expand on genome-wide studies of clozapine metabolism, previously focused on common genetic variation, by analysing whole-exome sequencing data from 2062 individuals with schizophrenia taking clozapine in the uk. |
2024-02-04 |
2024-02-07 |
Not clear |
| Deepak K Sarpal, Evan S Cole, Jessica M Gannon, Jie Li, Dale K Adair, K N Roy Chengappa, Julie M Donohu. Variation of Clozapine Use for Treatment of Schizophrenia: Evidence from Pennsylvania Medicaid and Dually Eligible Enrollees. Community mental health journal. 2024-01-31. PMID:38294579. |
variation of clozapine use for treatment of schizophrenia: evidence from pennsylvania medicaid and dually eligible enrollees. |
2024-01-31 |
2024-02-02 |
Not clear |
| Justin Faden, Leslie Citrom. A systematic review of clozapine for aggression and violence in patients with schizophrenia or schizoaffective disorder. Schizophrenia research. 2024-01-30. PMID:38290941. |
a systematic review of clozapine for aggression and violence in patients with schizophrenia or schizoaffective disorder. |
2024-01-30 |
2024-02-02 |
Not clear |